Molecular medicine and medical research
In 1941, at age 40, Pauling was diagnosed with a serious form of
Bright’s disease, a fatal renal disease. Experts believed then that Bright's disease was untreatable. With the help of
Dr. Thomas Addis at Stanford, Pauling was able to control the disease with Addis' then unusual, low protein, salt-free diet. Addis also prescribed vitamins and minerals for all his patients.
In 1951, Pauling gave a lecture entitled, "Molecular Medicine". In the late 1950s, Pauling worked on the role of enzymes in brain function, believing that mental illness may be partly caused by enzyme dysfunction. It wasn't until he read "
Niacin Therapy in Psychiatry" by Abram Hoffer in 1965 that he realized that vitamins might have important biochemical effects unrelated to their prevention of associated deficiency diseases. Pauling published a brief paper, "
Orthomolecular Psychiatry", in the journal Science in 1968 (PMID 5641253) that gave name and principle to the popular but controversial
megavitamin therapy movement of the 1970s. Pauling coined the term "
orthomolecular" to refer to the practice of varying the concentration of substances normally present in the body to prevent and treat disease. His ideas formed the basis of
orthomolecular medicine, which is not generally practiced by conventional medical professionals and is strongly criticized by some.
Pauling's work on
vitamin C in his later years generated controversy and was originally regarded by some adversaries in the field of medicine as outright
quackery.
He was first introduced to the concept of high-dose vitamin C by biochemist
Irwin Stone in 1966 and began taking several grams every day to prevent colds. Excited by the results, he researched the clinical literature and published "Vitamin C and the Common Cold" in 1970. He began a long clinical collaboration with the British cancer surgeon,
Ewan Cameron, in 1971 on the use of intravenous and oral vitamin C as cancer therapy for terminal patients. Cameron and Pauling wrote many technical papers and a popular book, "Cancer and Vitamin C", that discussed their observations. Three prospective, randomized, placebo-controlled trials were conducted by Moertel et al. at the Mayo Clinic; all three failed to prove a benefit for megadoses of vitamin C in cancer patients. Pauling denounced Charles Moertel's conclusions and handling of the final study as "fraud and deliberate misrepresentation." Pauling then published critiques of the second Mayo-Moertel cancer trial's flaws over several years as he was able to slowly unearth some of the trial's undisclosed details. However, the wave of adverse publicity generated by Moertel and the media effectively undercut Pauling's credibility and his vitamin C work for a generation, the oncological mainstream continued with other avenues of treatment. Always precariously perched since his molecular biologically inspired crusade to
stop atmospheric nuclear testing in the 1950s, the 1985 Mayo-Moertel confrontation left Pauling isolated from his institutional funding sources, academic support and a bemused public. He later collaborated with the Canadian physician,
Abram Hoffer, on a micronutrient regimen, including high-dose vitamin C, as adjunctive
cancer therapy.
As of 2006, new evidence of high-dose Vitamin C efficacy was proposed by a Canadian group of researchers. These researchers observed longer-than expected survival times in three patients treated with high doses of intravenous Vitamin C.
The researchers are reportedly planning a new
Phase I clinical trial
The selective toxicity of vitamin C for cancer cells has been demonstrated
in-vitro (i.e., in a
cell culture Petri dish), and was reported in 2005. The combination of case-report data and preclinical information suggest
biological plausibility and the possibility of clinical efficacy at the possible expense of critical toxicity at active doses; future clinical testing will ultimately determine the utility and safety of intravenous high-dose Vitamin C treatments for patients with cancer. Researchers released a paper demonstrating
in-vitro vitamin C killing of cancer cells in The Proceedings of the National Academy of Sciences in 2006
.
With two colleagues, Pauling founded the Institute of Orthomolecular Medicine in Menlo Park, California, in 1973, which was soon renamed the
Linus Pauling Institute of Science and Medicine. Pauling directed research on vitamin C, but also continued his theoretical work in chemistry and physics until his death. In his last years, he became especially interested in the possible role of vitamin C in preventing
atherosclerosis and published three case reports on the use of
lysine and vitamin C to relieve
angina pectoris. In 1996, the Linus Pauling Institute moved from Palo Alto, California, to Corvallis, Oregon, to become part of Oregon State University, where it continues to conduct research on
micronutrients, phytochemicals (chemicals from plants), and other constituents of the diet in preventing and treating disease. Several of the employees that had previously worked at the Linus Pauling Institute in Palo Alto moved on to form the
Genetic Information Research Institute.